AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.

T cells are important for the control of acute myeloid leukemia (AML), a common and often deadly malignancy. We observed that some AML patient samples are resistant to killing by human-engineered cytotoxic CD4 T cells. Single-cell RNA-seq of primary AML samples and CD4 T cells before and after their interaction uncovered transcriptional programs that correlate with AML sensitivity or resistance to CD4 T cell killing.